Previous Article 87 FR 166 pgs. 52781-52782 - Advisory Committee on Immunization Practices (ACIP)
Type: NOTICEVolume: 87Number: 166Pages: 52781 - 52782
Pages: 52781, 52782Docket number: [Docket No. CDC-2022-0103]
FR document: [FR Doc. 2022-18734 Filed 8-25-22; 4:15 pm]
Agency: Health and Human Services Department
Sub Agency: Centers for Disease Control and Prevention
Official PDF Version: PDF Version
[top]
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket No. CDC-2022-0103]
Advisory Committee on Immunization Practices (ACIP)
AGENCY:
Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).
ACTION:
Notice of meeting and request for comment.
SUMMARY:
In accordance with the Federal Advisory Committee Act, the Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces the following meeting of the Advisory Committee on Immunization Practices (ACIP). This meeting is open to the public. Time will be available for public comment.
DATES:
The meeting will be held on September 1, 2022, from 10:00 a.m. to 5:00 p.m., EDT and September 2, 2022, from 10:00 a.m. to 12:00 p.m., EDT (dates and times subject to change, see the ACIP website for updates http://www.cdc.gov/vaccines/acip/index.html ). The meeting will be webcast live via the World Wide Web. Written comments must be received on or before September 2, 2022.
ADDRESSES:
You may submit comments, identified by Docket No. CDC-2022-0103, by either of the following methods.
• Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments.
• Mail: Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS H24-8, Atlanta, GA 30329-4027, Attn: September 1-2, 2022, ACIP Meeting.
Instructions: All submissions received must include the Agency name and Docket Number. All relevant comments received will be posted without change to https://www.regulations.gov, including any personal information provided. For access to the docket to read background documents or comments received, go to https://www.regulations.gov.
FOR FURTHER INFORMATION CONTACT:
Stephanie Thomas, ACIP Committee Management Specialist, Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, 1600 Clifton Road NE, MS H24-8, Atlanta, GA 30329-4027; Telephone: 404-639-8367; Email: ACIP@cdc.gov.
SUPPLEMENTARY INFORMATION:
In accordance with 41 CFR 102-3.150(b), less than 15 calendar days' notice is being given for this meeting due to the exceptional circumstances of the COVID-19 pandemic and rapidly evolving COVID-19 vaccine development and regulatory processes. The Secretary of Health and Human Services has determined that COVID-19 is a Public Health Emergency. A notice of this Advisory Committee on Immunization Practices (ACIP) meeting has also been posted on CDC's ACIP website at: http://www.cdc.gov/vaccines/acip/index.html . In addition, CDC has sent notice of this ACIP meeting by email to those who subscribe to receive email updates about ACIP.
Purpose: The committee is charged with advising the Director, CDC, on the use of immunizing agents. In addition, under 42 U.S.C. 1396s, the committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children (VFC) program, along with schedules regarding dosing interval, dosage, and contraindications to administration of vaccines. Further, under provisions of the Affordable Care Act, section 2713 of the Public Health Service Act, immunization recommendations of the ACIP that have been approved by the CDC Director and appear on CDC immunization schedules must be covered by applicable health plans.
Matters To Be Considered: The agenda will include discussions on use of COVID-19 vaccines booster doses. A recommendation vote(s) is scheduled. Agenda items are subject to change as priorities dictate. For more information on the meeting agenda visit https://www.cdc.gov/vaccines/acip/meetings/index.html.
The meeting will be webcast live via the World Wide Web; for more information on ACIP, visit the ACIP website: http://www.cdc.gov/vaccines/acip/index.html.
Public Participation
[top] Interested persons or organizations are invited to participate by submitting written views, recommendations, and data. Please note that comments received, including attachments and other supporting materials, are part of the public record and are subject to
Written Public Comment: Written comments must be received on or before September 2, 2022.
Oral Public Comment: This meeting will include time for members of the public to make an oral comment. Oral public comment will occur before any scheduled votes including all votes relevant to the ACIP's Affordable Care Act and Vaccines for Children Program roles. Priority will be given to individuals who submit a request to make an oral public comment before the meeting according to the procedures below.
Procedure for Oral Public Comment: All persons interested in making an oral public comment during the September 1-2, 2022, ACIP meeting must submit a request at https://www.cdc.gov/vaccines/acip/meetings/ no later than 11:59 p.m. EDT, August 30, 2022, according to the instructions provided.
If the number of persons requesting to speak is greater than can be reasonably accommodated during the scheduled time, CDC will conduct a lottery to determine the speakers for the scheduled public comment session. CDC staff will notify individuals by email on August 31, 2022, regarding their request to speak. To accommodate the significant interest in participation in the oral public comment session of ACIP meetings, each speaker will be limited to three minutes, and each speaker may only speak once per meeting.
The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2022-18734 Filed 8-25-22; 4:15 pm]
BILLING CODE 4163-18-P